Figure 3 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
<p>Effect of NKCEs targeting CD19 or CD20 on primary BCP-ALL cells. <b>A,</b> Phenotypic characterization via flow cytometry of four BCP-ALL primary leukemia samples, using CD45-APC-Vio770, CD19-PE-Cy7, and CD20-V450. <b>B,</b> 7AAD/AnnV staining of cells from sample AL...
Guardat en:
| Autor principal: | |
|---|---|
| Altres autors: | , , , , , , , , , , , , , |
| Publicat: |
2025
|
| Matèries: | |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
| _version_ | 1849927631565225984 |
|---|---|
| author | Natalia Colomar-Carando (14611340) |
| author2 | Laurent Gauthier (15129623) Pietro Merli (15129626) Fabrizio Loiacono (5306981) Paolo Canevali (332990) Michela Falco (368897) Federica Galaverna (8825531) Benjamin Rossi (15129629) Frédéric Bosco (15129632) Mélody Caratini (15129635) Maria Cristina Mingari (8409327) Franco Locatelli (15127797) Eric Vivier (48284) Raffaella Meazza (7179467) Daniela Pende (15129638) |
| author2_role | author author author author author author author author author author author author author author |
| author_facet | Natalia Colomar-Carando (14611340) Laurent Gauthier (15129623) Pietro Merli (15129626) Fabrizio Loiacono (5306981) Paolo Canevali (332990) Michela Falco (368897) Federica Galaverna (8825531) Benjamin Rossi (15129629) Frédéric Bosco (15129632) Mélody Caratini (15129635) Maria Cristina Mingari (8409327) Franco Locatelli (15127797) Eric Vivier (48284) Raffaella Meazza (7179467) Daniela Pende (15129638) |
| author_role | author |
| dc.creator.none.fl_str_mv | Natalia Colomar-Carando (14611340) Laurent Gauthier (15129623) Pietro Merli (15129626) Fabrizio Loiacono (5306981) Paolo Canevali (332990) Michela Falco (368897) Federica Galaverna (8825531) Benjamin Rossi (15129629) Frédéric Bosco (15129632) Mélody Caratini (15129635) Maria Cristina Mingari (8409327) Franco Locatelli (15127797) Eric Vivier (48284) Raffaella Meazza (7179467) Daniela Pende (15129638) |
| dc.date.none.fl_str_mv | 2025-11-25T13:42:40Z |
| dc.identifier.none.fl_str_mv | 10.1158/2326-6066.30710197 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Figure_3_from_Exploiting_Natural_Killer_Cell_Engagers_to_Control_Pediatric_B-cell_Precursor_Acute_Lymphoblastic_Leukemia/30710197 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Immuno-oncology Hematological Cancers Leukemias Immunology NK cells Immunotherapy Stem cell transplantation |
| dc.title.none.fl_str_mv | Figure 3 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Effect of NKCEs targeting CD19 or CD20 on primary BCP-ALL cells. <b>A,</b> Phenotypic characterization via flow cytometry of four BCP-ALL primary leukemia samples, using CD45-APC-Vio770, CD19-PE-Cy7, and CD20-V450. <b>B,</b> 7AAD/AnnV staining of cells from sample ALL#06 cultured either alone (only ALL#06) or with resting NK cells from a representative healthy donor and the indicated NKCEs (10<sup>0</sup> μg/mL). <b>C,</b> CD107a expression of NK cells cultured either alone or with cells from ALL#06 in the presence of IC-NKp46-NKCE, CD19-NKp46-NKCE, or CD20-NKp46-NKCE (10<sup>0</sup> μg/mL). A representative experiment is shown. Numbers indicate the percentage of cells in each quadrant. <b>D,</b> Percent of specific lysis of CD19<sup>+</sup> leukemia blasts (left) and CD107a degranulation (right) of resting NK cells from healthy donors (<i>n</i> = 3–6) upon coculture with primary leukemia blasts and NKCEs at 10<sup>0</sup> μg/mL as indicated. Data obtained with target cells containing leukemia blasts <85% (ALL#02 and ALL#07) or >85% (ALL#04 and ALL#06) were pooled. Results from 2–5 independent experiments are reported. The incubation time for all the tests was 4 hours. Bar show mean ± SEM. Statistical significance: *, <i>P</i> ≤ 0.05; **, <i>P</i> ≤ 0.01; ***, <i>P</i> ≤ 0.001. Mann–Whitney test was used to calculate statistical differences.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_3fd965207d3638de8717553a77791508 |
| identifier_str_mv | 10.1158/2326-6066.30710197 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30710197 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Figure 3 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic LeukemiaNatalia Colomar-Carando (14611340)Laurent Gauthier (15129623)Pietro Merli (15129626)Fabrizio Loiacono (5306981)Paolo Canevali (332990)Michela Falco (368897)Federica Galaverna (8825531)Benjamin Rossi (15129629)Frédéric Bosco (15129632)Mélody Caratini (15129635)Maria Cristina Mingari (8409327)Franco Locatelli (15127797)Eric Vivier (48284)Raffaella Meazza (7179467)Daniela Pende (15129638)CancerImmuno-oncologyHematological CancersLeukemiasImmunologyNK cellsImmunotherapyStem cell transplantation<p>Effect of NKCEs targeting CD19 or CD20 on primary BCP-ALL cells. <b>A,</b> Phenotypic characterization via flow cytometry of four BCP-ALL primary leukemia samples, using CD45-APC-Vio770, CD19-PE-Cy7, and CD20-V450. <b>B,</b> 7AAD/AnnV staining of cells from sample ALL#06 cultured either alone (only ALL#06) or with resting NK cells from a representative healthy donor and the indicated NKCEs (10<sup>0</sup> μg/mL). <b>C,</b> CD107a expression of NK cells cultured either alone or with cells from ALL#06 in the presence of IC-NKp46-NKCE, CD19-NKp46-NKCE, or CD20-NKp46-NKCE (10<sup>0</sup> μg/mL). A representative experiment is shown. Numbers indicate the percentage of cells in each quadrant. <b>D,</b> Percent of specific lysis of CD19<sup>+</sup> leukemia blasts (left) and CD107a degranulation (right) of resting NK cells from healthy donors (<i>n</i> = 3–6) upon coculture with primary leukemia blasts and NKCEs at 10<sup>0</sup> μg/mL as indicated. Data obtained with target cells containing leukemia blasts <85% (ALL#02 and ALL#07) or >85% (ALL#04 and ALL#06) were pooled. Results from 2–5 independent experiments are reported. The incubation time for all the tests was 4 hours. Bar show mean ± SEM. Statistical significance: *, <i>P</i> ≤ 0.05; **, <i>P</i> ≤ 0.01; ***, <i>P</i> ≤ 0.001. Mann–Whitney test was used to calculate statistical differences.</p>2025-11-25T13:42:40ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/2326-6066.30710197https://figshare.com/articles/figure/Figure_3_from_Exploiting_Natural_Killer_Cell_Engagers_to_Control_Pediatric_B-cell_Precursor_Acute_Lymphoblastic_Leukemia/30710197CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307101972025-11-25T13:42:40Z |
| spellingShingle | Figure 3 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia Natalia Colomar-Carando (14611340) Cancer Immuno-oncology Hematological Cancers Leukemias Immunology NK cells Immunotherapy Stem cell transplantation |
| status_str | publishedVersion |
| title | Figure 3 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia |
| title_full | Figure 3 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia |
| title_fullStr | Figure 3 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia |
| title_full_unstemmed | Figure 3 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia |
| title_short | Figure 3 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia |
| title_sort | Figure 3 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia |
| topic | Cancer Immuno-oncology Hematological Cancers Leukemias Immunology NK cells Immunotherapy Stem cell transplantation |